Merck & Co., Inc. (MRK) stock
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30285% above fair value
$143.37−1.09 (-0.75%)
Close on Nov 17, 2026Market cap $353.72BP/E 114.7Yield 2.29%
Merck total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Merck's total debt was $53.91B at Jun 30, 2026. For fiscal 2025 it was $49.34B, up 32.9% from the year before. Over ten years it grew 6.4% a year on average. The highest annual figure on record is $49.34B in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.34B | +32.9% |
| FY2024 | Dec 31, 2024 | $37.11B | +5.9% |
| FY2023 | Dec 31, 2023 | $35.06B | +14.2% |
| FY2022 | Dec 31, 2022 | $30.69B | -7.3% |
| FY2021 | Dec 31, 2021 | $33.10B | +4.1% |
| FY2020 | Dec 31, 2020 | $31.79B | +20.7% |
| FY2019 | Dec 31, 2019 | $26.35B | +4.9% |
| FY2018 | Dec 31, 2018 | $25.11B | +2.9% |
| FY2017 | Dec 31, 2017 | $24.41B | -1.7% |
| FY2016 | Dec 31, 2016 | $24.84B | -5.9% |
| FY2015 | Dec 31, 2015 | $26.41B | +23.4% |
| FY2014 | Dec 31, 2014 | $21.40B | -14.6% |
| FY2013 | Dec 31, 2013 | $25.06B | +21.8% |
| FY2012 | Dec 31, 2012 | $20.57B | +17.4% |
| FY2011 | Dec 31, 2011 | $17.52B | -2.1% |
| FY2010 | Dec 31, 2010 | $17.88B | +2.3% |
| FY2009 | Dec 31, 2009 | $17.47B | +180.0% |
| FY2008 | Dec 31, 2008 | $6.24B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $53.91B | +52.3% |
| Q1 FY2026 | Mar 31, 2026 | $49.12B | +41.0% |
| Q4 FY2025 | Dec 31, 2025 | $49.34B | +32.9% |
| Q3 FY2025 | Sep 30, 2025 | $41.37B | +8.5% |
| Q2 FY2025 | Jun 30, 2025 | $35.40B | -6.3% |
| Q1 FY2025 | Mar 31, 2025 | $34.84B | +1.8% |
| Q4 FY2024 | Dec 31, 2024 | $37.11B | +5.9% |
| Q3 FY2024 | Sep 30, 2024 | $38.13B | +9.4% |
| Q2 FY2024 | Jun 30, 2024 | $37.79B | +2.4% |
| Q1 FY2024 | Mar 31, 2024 | $34.22B | +11.3% |
| Q4 FY2023 | Dec 31, 2023 | $35.06B | +14.2% |
| Q3 FY2023 | Sep 30, 2023 | $34.86B | +14.6% |
| Q2 FY2023 | Jun 30, 2023 | $36.91B | +16.6% |
| Q1 FY2023 | Mar 31, 2023 | $30.75B | -3.3% |
| Q4 FY2022 | Dec 31, 2022 | $30.69B | -7.3% |
| Q3 FY2022 | Sep 30, 2022 | $30.42B | +15.0% |
| Q2 FY2022 | Jun 30, 2022 | $31.66B | +19.4% |
| Q1 FY2022 | Mar 31, 2022 | $31.79B | +1.7% |
| Q4 FY2021 | Dec 31, 2021 | $33.10B | +4.1% |
| Q3 FY2021 | Sep 30, 2021 | $26.44B | -8.0% |
| Q2 FY2021 | Jun 30, 2021 | $26.52B | -14.1% |
| Q1 FY2021 | Mar 31, 2021 | $31.25B | +11.6% |
| Q4 FY2020 | Dec 31, 2020 | $31.79B | +20.7% |
| Q3 FY2020 | Sep 30, 2020 | $28.74B | +10.2% |
| Q2 FY2020 | Jun 30, 2020 | $30.87B | +16.1% |
| Q1 FY2020 | Mar 31, 2020 | $28.00B | +8.1% |
| Q4 FY2019 | Dec 31, 2019 | $26.35B | +4.9% |
| Q3 FY2019 | Sep 30, 2019 | $26.09B | +10.6% |
| Q2 FY2019 | Jun 30, 2019 | $26.59B | +13.9% |
| Q1 FY2019 | Mar 31, 2019 | $25.90B | +9.9% |
| Q4 FY2018 | Dec 31, 2018 | $25.11B | +2.9% |
| Q3 FY2018 | Sep 30, 2018 | $23.59B | -12.6% |
| Q2 FY2018 | Jun 30, 2018 | $23.34B | -6.2% |
| Q1 FY2018 | Mar 31, 2018 | $23.56B | -17.3% |
| Q4 FY2017 | Dec 31, 2017 | $24.41B | -1.7% |
| Q3 FY2017 | Sep 30, 2017 | $27.00B | +7.4% |
| Q2 FY2017 | Jun 30, 2017 | $24.89B | – |
| Q1 FY2017 | Mar 31, 2017 | $28.47B | – |
| Q4 FY2016 | Dec 31, 2016 | $24.84B | – |
| Q3 FY2016 | Sep 30, 2016 | $25.14B | – |
See a number that looks wrong?